|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013018,
umls-concept:C0030705,
umls-concept:C0079189,
umls-concept:C0087111,
umls-concept:C0205112,
umls-concept:C0278678,
umls-concept:C0332293,
umls-concept:C0443315,
umls-concept:C1527169,
umls-concept:C1707455,
umls-concept:C1979963,
umls-concept:C2003903
|
|
pubmed:dateCreated |
2007-12-31
|
|
pubmed:abstractText |
Metastatic renal cell carcinoma (MRCC) has a poor prognosis with a median overall survival of about one year. Since only a minority of patients experienced therapeutic benefit to current treatments, several studies have attempted to identify factors that may have an impact on response and survival. Cytokines play a crucial role in the host's immune response by regulating the development and function of a lot of biological compartments. Nevertheless, available data on basal cytokine levels in MRCC are very few and no clear profile of serum cytokines has been identified yet in these patients population. Thus, determining the levels of cytokines in MRCC could not only help in understanding the biological mechanisms of the tumor growth, but also in evaluating if different cytokine profiles are correlated with particular clinical behaviors.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-11577478,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-11687446,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-11981011,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-12196373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-12209689,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-12569375,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-12814677,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-1498066,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-16423296,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-17215529,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-17215530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-7855619,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-9159205,
http://linkedlifedata.com/resource/pubmed/commentcorrection/17953739-9562581
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1479-5876
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
51
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17953739-Analysis of Variance,
pubmed-meshheading:17953739-Antineoplastic Agents,
pubmed-meshheading:17953739-C-Reactive Protein,
pubmed-meshheading:17953739-Carcinoma, Renal Cell,
pubmed-meshheading:17953739-Cytokines,
pubmed-meshheading:17953739-Humans,
pubmed-meshheading:17953739-Inflammation,
pubmed-meshheading:17953739-Interleukin-2,
pubmed-meshheading:17953739-Kidney Neoplasms,
pubmed-meshheading:17953739-Neoplasm Metastasis,
pubmed-meshheading:17953739-Reference Values,
pubmed-meshheading:17953739-Statistics, Nonparametric,
pubmed-meshheading:17953739-Survival Analysis,
pubmed-meshheading:17953739-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors.
|
|
pubmed:affiliation |
Department of Medical Oncology, National Oncology Institute, Bari, Italy. micguida@libero.it
|
|
pubmed:publicationType |
Journal Article
|
